Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Earnings Results, Beats Estimates By $0.06 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) issued its quarterly earnings data on Monday. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of Damora Therapeutics, Inc. Common Stock stock traded down $0.38 during midday trading on Monday, hitting $29.54. The company had a trading volume of 216,195 shares, compared to its average volume of 388,762. Damora Therapeutics, Inc. Common Stock has a 1-year low of $2.45 and a 1-year high of $38.33. The business’s 50 day simple moving average is $26.46 and its two-hundred day simple moving average is $26.28. The stock has a market cap of $1.82 billion, a PE ratio of -5.29 and a beta of 1.47.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of DMRA. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $40,000. Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at about $49,000. Two Sigma Investments LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $76,000. Finally, Connective Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $100,000. 14.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DMRA has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. Wedbush raised their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.00.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.